Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Queen Mary University of London
Deal Size : Inapplicable
Deal Type : Inapplicable
Hyaluronic Acid and Polynucleotides for Supra-bony Defects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 13, 2024
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Queen Mary University of London
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taurolidine
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : PerioSept
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 18, 2019
Lead Product(s) : Taurolidine
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Misetionamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Translational Drug Development
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2019
Lead Product(s) : Misetionamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Translational Drug Development
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Toluidine Blue
Therapeutic Area : Dental and Oral Health
Study Phase : Undisclosed
Recipient : University of Sao Paulo
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Antimicrobial Photodynamic Therapy on Regeneration of Class II Furcation Lesions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 28, 2017
Lead Product(s) : Toluidine Blue
Therapeutic Area : Dental and Oral Health
Highest Development Status : Undisclosed
Recipient : University of Sao Paulo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Geistlich Bio-Oss
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : The Baruch Padeh Medical Center, Poriya
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 27, 2016
Lead Product(s) : Geistlich Bio-Oss
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : The Baruch Padeh Medical Center, Poriya
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deproteinized Bovine Bone
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Recipient : University of Padova, School of Dental Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Deproteinized Bovine Bone in Alveolar Bone Critical Size Defect (>2cm) Secondary to Cyst Removal
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 24, 2015
Lead Product(s) : Deproteinized Bovine Bone
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Recipient : University of Padova, School of Dental Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taurolidine
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : PerioSept
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 10, 2014
Lead Product(s) : Taurolidine
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
